Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC - 06/10/23
Highligths |
• | Albumine infusion during Atezolizumab-Bevacizumab in Child-Pugh B patients reduce expansion/development of ascites |
• | Albumine infusion during Atezolizumab-Bevacizumab in Child-Pugh B patients do not improve overall survival |
• | Similar rate of hepatic encephatolopathy and acute variceal bleeding were observed in Child-Pugh B patients who received or not albumin infusion in combination with Atezolizumab-Bevacizumab |
Abstract |
Background |
Long-term albumin infusions have been associated with improved outcomes in decompensated cirrhotic patients. This study aimed to evaluate the impact of albumin infusion on the prognosis of Child-Pugh B patients undergoing treatment with AtezoBev for advanced hepatocellular carcinoma (HCC).
Methods |
We conducted a retrospective multicentric study that included all Child-Pugh B cirrhotic patients treated with AtezoBev since 2020. We examined the effects of albumin infusion (40 g every 3 weeks) on overall survival (OS) and the occurrence of cirrhosis-related complications. Time-to-event data were analyzed using Kaplan-Meier with the log-rank test and Cox models.
Results |
Forty-seven HCC patients with a Child-Pugh B score who received AtezoBev were included, of whom 26% also received albumin infusions every 3 weeks. The two groups were similar in terms of liver function and HCC parameters. The median OS was 4.4 and 5.8 months (p = 0.42) for patients who did or did not receive albumin, respectively. The occurrence of hepatic encephalopathy and variceal bleeding was similar between the two groups. However, albumin infusions were associated with a significantly lower rate of ascites expansion/development (13% versus 57%, p = 0.005). Cox analysis revealed that a history of ascites (HR=3.82 [95% CI: 1.73–8.48]) was independently associated with a higher risk of ascites expansion/development, whereas albumin infusions were protective (HR=0.07 [95% CI: 0.01–0.54]).
Conclusions |
Albumin infusion did not improve overall survival in Child-Pugh B HCC patients treated with AtezoBev, but it significantly reduced the expansion/development of ascites.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatocellular carcinoma, Albumin, Overall survival, Atezolizumab-Bevacizumab, prognostic factors
Abbreviations : 95% CI, AFP, ALBI grade, ALP, ALT, AST, AtezoBev, AVB, BCLC, CT, EV, GGT, HCC, HR, INR, MELD, MR, NSBB, OS, PFS, PHT, PT, PVTT, SD, TIPS
Plan
Vol 47 - N° 8
Article 102199- octobre 2023 Retour au numéro
Article précédent
- An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patients
- Yueping Liu, Meiling Sun
- Are children with gallstone disease more overweight? Results of a matched case-control analysis
- Marcin Krawczyk, Zbigniew Kułaga, Olga Niewiadomska, Irena Jankowska, Dariusz Lebensztejn, Sabina Więcek, Piotr Socha
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?